Wedbush analyst Laura Chico maintained a Buy rating on PepGen Inc. (PEPG – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $13.99.
Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Ultragenyx Pharmaceutical, and Pharvaris. According to TipRanks, Chico has an average return of 1.9% and a 45.66% success rate on recommended stocks.
Currently, the analyst consensus on PepGen Inc. is a Strong Buy with an average price target of $22.25, implying a 59.04% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.
Based on PepGen Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $23.29 million. In comparison, last year the company had a GAAP net loss of $14.96 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PepGen Inc. (PEPG) Company Description:
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.
